Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||C220 + Ruxolitinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|C220||PRMT5 Inhibitor 11||C220 is a small molecule inhibitor that selectively targets PRMT5, which may lead to decreased cell proliferation and reduced secretion of cytokines (PMID: 32669286).|
|Ruxolitinib||Jakafi||INCB 18424|INCB018424|INCB18424||JAK1 Inhibitor - ATP competitive 5 JAK2 Inhibitor - ATP competitive 15||Jakafi (ruxolitinib) is an inhibitor of protein tyrosine kinases JAK1 and JAK2, thus resulting in reduced inflammation and reduced proliferation (PMID: 22474318). Jakafi (ruxolitinib) is FDA approved to treat bone marrow cancer, specifically intermediate or high-risk myelofibrosis (FDA.gov)|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|JAK2 V617F||polycythemia vera||predicted - sensitive||C220 + Ruxolitinib||Preclinical||Actionable||In a preclinical study, combination of C220 and Jakafi (ruxolitinib) treatment in a transgenic mouse model of polycythemia vera expressing JAK2 V617F resulted in reduced white blood cell count, decreased spleen and liver size, reduced bone marrow hypercellularity, reduced erythroid, megakaryocyte and myeloid progenitors, and inhibition of inflammatory cytokines to a greater degree than single agent alone. (PMID: 32669286).||32669286|
|JAK2 V617F||myeloproliferative neoplasm||predicted - sensitive||C220 + Ruxolitinib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, combination of C220 and Jakafi (ruxolitinib) treatment led to additive effects, resulting in inhibition of proliferation of myeloproliferative neoplasm cell lines expressing JAK2 V617F in culture, and inhibited tumor growth, with a 73% tumor reduction, in a cell line xenograft model (PMID: 32669286).||32669286|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|